0001209191-15-069921.txt : 20150909
0001209191-15-069921.hdr.sgml : 20150909
20150909162857
ACCESSION NUMBER: 0001209191-15-069921
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150904
FILED AS OF DATE: 20150909
DATE AS OF CHANGE: 20150909
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 151099157
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-09-04
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP\Chief Commercial Officer
Common Stock
2015-09-04
4
M
0
9063
53.74
A
136578
D
Common Stock
2015-09-04
4
S
0
400
124.43
D
136178
D
Common Stock
2015-09-04
4
S
0
5200
125.42
D
130978
D
Common Stock
2015-09-04
4
S
0
3463
126.44
D
127515
D
Common Stock
140
I
401(k)
Stock Option (right to buy)
53.74
2015-09-04
4
M
0
9063
0.00
D
2022-09-03
Common Stock
9063
18125
D
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $124.43 (range $123.98 to $124.85).
Open market sales reported on this line occurred at a weighted average price of $125.42 (range $124.99 to $125.98).
Open market sales reported on this line occurred at a weighted average price of $126.44 (range $126.00 to $126.92).
The option vests in 16 quarterly installments from 09/04/2012.
Omar White, Attorney-In-Fact
2015-09-09